Our Foundation:
Photoaffinity Labeling
ALT
BioScience™ built it’s foundation
on patented technology called nucleotide
photoaffinity labeling. This technology
is a photochemical process that enables
specific attachment of a radioactive nucleotide
to specific enzymes at their active sites.
As nucleotide
binding proteins vary in diseased verses
normal or healthy tissues, nucleotide
photoaffinity labeling technology allows
for the identification of various enzyme
and protein differences between normal
and
diseased tissues such as Alzheimer’s
and Lou Gehrig’s Disease (ALS).
The development
of the technology was supported
by continuing NIH grants for over
25 years and has become an integral research
tool
for nearly 300 academic research
institutions,
biotech and pharmaceutical companies
worldwide.
Many
research applications have been identified
and published using Nucleotide Photoaffinity
Labeling such as enzymological studies
for
active catalytic site identification
and the detection of aberrant nucleotide
binding
proteins in diverse tissues in cancer,
Alzheimer’s,
and bacterial infections.
Nucleotide
Photoaffinity Labeling is also
used for clinical testing
of the effects of toxic compounds
on tissues and for the rapid production
of radiolabeled
antibodies and super-antibodies
which
retain most or all of their antigen
recognition ability. These radiolabeled
antibodies
are
being used in radio-immunoassays
verses radio-iodinated antibodies, comparatively.
Compounds
are also available that allow
for rapid simple introduction
of biotin into any primary antibody for
conventional
biotin-avidin based immunology.
